ALLOGENE THERAPEUTICS INC (ALLO) Stock News
NASDAQ:ALLO - Nasdaq - US0197701065 - Common Stock - Currency: USD
ALLO Latest News, Press Relases and Analysis
Tuesday's session: gap up and gap down stocks
Let's have a look at the gap up and gap down stocks in today's session.
Friday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
What's going on in today's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Friday's session: gap up and gap down stocks
In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
Efficacy Comparable to Approved Autologous CD19 CAR Ts: Achieved Overall Response (ORR) and Complete Response (CR) Rates of 58% and 42% Across the Study...
Allogene Therapeutics Announces Participation in February Investor Conferences
Allogene Therapeutics Announces Participation in February Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune...
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
/PRNewswire/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never...
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allogene Therapeutics Announces Participation in December Investor Conferences
Allogene Therapeutics Announces Participation in December Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine...
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and...